| Clinical data | |
|---|---|
| Other names | N,N-Diethyl-6-cyclopropyl-6-norlysergamide; 6-Cyclopropyl-6-norlysergic acid diethylamide; 6-Cyclopropyl-6-nor-LSD; TRALA-22; 6-Cyclopropyl-N,N-diethyl-9,10-didehydroergoline-8β-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C22H27N3O |
| Molar mass | 349.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
CYP-LAD, also known as6-cyclopropyl-6-nor-lysergic acid diethylamide or asTRALA-22, is alysergamide andanalogue oflysergic acid diethylamide (LSD).[1] It waspatented byDaniel Trachsel and colleagues in 2023 as an LSD analogue with modified LSD-like action,[1] and had also previously been claimed in a 2022 patent byGilgamesh Pharmaceuticals.[2]
Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |